Harborside


Revive Therapeutics Ltd.

CNSX: RVV


Canadian symbol: RVV.CN
US symbol: RVVTF

Currency in CAD

Valuation Measures4

Market Cap (intraday) 174.88M
Enterprise Value 158.69M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)5.85
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -7.92

Trading Information

Stock Price History

Beta (5Y Monthly) 0.07
52-Week Change 325.32%
S&P500 52-Week Change 322.93%
52 Week High 30.9200
52 Week Low 30.3050
50-Day Moving Average 30.4835
200-Day Moving Average 30.4820

Share Statistics

Avg Vol (3 month) 3430.63k
Avg Vol (10 day) 3403.02k
Shares Outstanding 5317.96M
Implied Shares Outstanding 6N/A
Float 8311.43M
% Held by Insiders 12.23%
% Held by Institutions 12.59%
Shares Short (Nov. 14, 2021) 4159.41k
Short Ratio (Nov. 14, 2021) 40.37
Short % of Float (Nov. 14, 2021) 4N/A
Short % of Shares Outstanding (Nov. 14, 2021) 40.05%
Shares Short (prior month Oct. 14, 2021) 4350.35k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Jun. 29, 2021
Most Recent Quarter (mrq)Sep. 29, 2021

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-61.96%
Return on Equity (ttm)-121.97%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -18.91M
Net Income Avi to Common (ttm)-20.47M
Diluted EPS (ttm)-0.0700
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)14.82M
Total Cash Per Share (mrq)0.05
Total Debt (mrq)395.8k
Total Debt/Equity (mrq)1.64
Current Ratio (mrq)4.32
Book Value Per Share (mrq)0.08

Cash Flow Statement

Operating Cash Flow (ttm)-9.15M
Levered Free Cash Flow (ttm)-5.6M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
RVV.CN
Revive Therapeutics
2 days ago
RVV.CN
Revive Therapeutics
1 month ago
RVV.CN
Revive Therapeutics
1 month ago
RVV.CN
Revive Therapeutics
3 months ago
RVV.CN
Revive Therapeutics
3 months ago
RVV.CN
Revive Therapeutics
4 months ago
RVV.CN
Revive Therapeutics
4 months ago
RVV.CN
Revive Therapeutics
5 months ago
RVV.CN
Revive Therapeutics
7 months ago
RVV.CN
Revive Therapeutics
9 months ago
RVV.CN
Revive Therapeutics
9 months ago
RVV.CN
Revive Therapeutics
9 months ago
RVV.CN
Revive Therapeutics
9 months ago
RVV.CN
Revive Therapeutics
9 months ago
RVV.CN
Revive Therapeutics
10 months ago
RVV.CN
Revive Therapeutics
10 months ago
RVV.CN
Revive Therapeutics
10 months ago
RVV.CN
Revive Therapeutics
10 months ago
RVV.CN
Revive Therapeutics
11 months ago
RVV.CN
Revive Therapeutics
11 months ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
1 year ago
RVV.CN
Revive Therapeutics
2 years ago
RVV.CN
Revive Therapeutics
2 years ago
RVV.CN
Revive Therapeutics
2 years ago
RVV.CN
Revive Therapeutics
2 years ago
RVV.CN
Revive Therapeutics
2 years ago
RVV.CN
Revive Therapeutics
2 years ago
RVV.CN
Revive Therapeutics
2 years ago
RVV.CN
Revive Therapeutics
2 years ago
RVV.CN
Revive Therapeutics
2 years ago
RVV.CN
Revive Therapeutics
2 years ago

Analysts data is not available


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
2.23%% of Shares Held by All Insider
2.59%% of Shares Held by Institutions
2.65%% of Float Held by Institutions
8Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Gofen & Glossberg LLC150,000Sep. 29, 20210.21%67,500
HighPoint Advisor Group LLC18,496Sep. 29, 20210.03%8,323
Captrust Financial Advisors15,510Sep. 29, 20210.02%6,979
Ifp Advisors, Inc5,000Sep. 29, 20210.01%2,250
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Revive Therapeutics Ltd.


UPDATE -- Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

UPDATE — Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding inflammatory markers along with viral load testing to current Phase 3 clinical study for COVID-19 aiming to strengthen Bucillamine’s profile as b... Read More...
Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding inflammatory markers along with viral load testing to current Phase 3 clinical study for COVID-19 aiming to strengthen Bucillamine’s profile as b... Read More...
Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

TORONTO, Nov. 23, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has filed an application with the U.S. Food and Drug Administrat... Read More...
Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant

Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant

TORONTO, Nov. 16, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a research study, titled “Thiol drugs decrease SARS-CoV-2 lung injury in ... Read More...
Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF

Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF

TORONTO, Sept. 21, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today that AdvisorShares® Investments LLC (“AdvisorShares”), a leading sponsor... Read More...
Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer

Revive Therapeutics Signs Exclusive Worldwide License Agreement For Medicinal Mushroom Ganoderma Lucidum To Treat Cancer

Novel discovery and research originated from Universidad Central del Caribe and St. Jude Children’s Research HospitalMedicinal mushroom compound with anticancer activities that have minimal effects on normal cellsShowed superior potency against aggressive breast cancer with potential to treat aggressive malignancies such as triple negativ... Read More...
Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline

Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline

Focusing on novel uses, production and delivery forms of psilocybin as a next generation solution for mental illness, substance abuse and neurological disordersAdvancing to FDA clinical studies for methamphetamine use disorder and stroke TORONTO, Aug. 10, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RV... Read More...
Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics

Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics

TORONTO, June 17, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into an agreement with the University of Health Science... Read More...
Revive To Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference

Revive To Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference

TORONTO, June 14, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced that Derrick Welsh, COO of Psilocin Pharma Corp., a division of the Company, ... Read More...
Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India

Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India

TORONTO, June 08, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a memorandum of understanding dated June 7, 2021 w... Read More...
Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip

Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip

TORONTO, May 17, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a feasibility agreement with LTS Lohmann Therapie-S... Read More...
Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19

Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19

TORONTO, May 03, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into a sponsored research agreement with University... Read More...
Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury

Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury

TORONTO, April 27, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has filed an application with the U.S. Food and Drug Administration ("FDA") to rec... Read More...
Revive Reschedules Annual and Special Meeting and Provides Dial-In Information

Revive Reschedules Annual and Special Meeting and Provides Dial-In Information

TORONTO, April 15, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to announce that, further to its press release of April 12, 2021, its Annual and Special Meeting ... Read More...
Revive Provides Dial-In Information for Annual and Special Meeting

Revive Provides Dial-In Information for Annual and Special Meeting

TORONTO, April 08, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, would like to provide the following dial-in information for the Company’s upcoming Annual and Special Meetin... Read More...
UPDATE -- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request

UPDATE — Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request

TORONTO, Feb. 26, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinica... Read More...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request

TORONTO, Feb. 26, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinica... Read More...
Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering

Revive Therapeutics Announces Closing of $23.0 Million Short Form Prospectus Offering

TORONTO, Feb. 12, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has closed its previously announced bought deal prospectus offering of 46,000,... Read More...
Revive Therapeutics Provides Update on Cannabinoid Pharmaceuticals Program

Revive Therapeutics Provides Update on Cannabinoid Pharmaceuticals Program

TORONTO, Feb. 11, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide a corporate update on its cannabinoid pharmaceuticals program specifically as it relate... Read More...
Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering

Revive Therapeutics Receives Receipt for Final Short-Form Prospectus for Previously Announced $20 Million Bought Deal Public Offering

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATESTORONTO, Feb. 09, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce th... Read More...
Revive Therapeutics Included in First Psychedelic Exchange Traded Fund

Revive Therapeutics Included in First Psychedelic Exchange Traded Fund

TORONTO, Jan. 22, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it is one of the seventeen companies in the U.S. and Canada that will be included... Read More...
Revive Therapeutics Announces Upsize to Previously Announced Bought Deal Offering

Revive Therapeutics Announces Upsize to Previously Announced Bought Deal Offering

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/TORONTO, Jan. 21, 2021 - Revive Therapeutics Ltd. ("Revive" or the "Company") (CSE:RVV) (USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce t... Read More...
Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

TORONTO, Jan. 14, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a sponsored research agreement and an exclusive option to license ... Read More...
Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

TORONTO, Dec. 31, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. John Fahy, MD, MSc, as a Scientific and Clinical advisor to the... Read More...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Plans on Emergency Use Access

TORONTO, Dec. 23, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinica... Read More...
Revive Therapeutics Announces LOI to Acquire PharmaTher's Psilocybin Program

Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program

TORONTO, Dec. 21, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”), dated December 20... Read More...
PharmaTher Signs LOI to Sell Psilocybin Program to Revive Therapeutics

PharmaTher Signs LOI to Sell Psilocybin Program to Revive Therapeutics

PharmaTher to focus on FDA human clinical trials of ketamine for Parkinson’s disease, depression and painTORONTO, Dec. 21, 2020 -- PharmaTher Inc., (“PharmaTher” or the “Company”), a wholly-owned subsidiary of Newscope Capital Corporation (CSE: PHRM) (OTC Pink: PHRRF) and a specialty life sciences company focused on the research and devel... Read More...
Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor

Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor

TORONTO, Dec. 02, 2020 -- Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company... Read More...
Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics

Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics

TORONTO, Nov. 18, 2020 -- Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into an exclusive research collaboration agreement with PharmaTher Inc., a wholly-owned ... Read More...
Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin

Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin

TORONTO, Nov. 11, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on its oral thin-film delivery system with psilocybin being developed under a... Read More...
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Oct. 26, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 cl... Read More...
Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds

Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds

TORONTO, Oct. 20, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has signed a supply agreement (the “Agreement”) with Havn Life Sciences Inc. (CSE :... Read More...
Revive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Sept. 29, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 c... Read More...
Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs

Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs

TORONTO, Sept. 21, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide a corporate update on its psychedelics therapeutics programs specifically as it relates... Read More...
Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

TORONTO, Sept. 16, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company’s expanded access protocol (“EAP”) for compassionate use of Bucillam... Read More...
Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder

Revive Therapeutics Enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder

TORONTO, Sept. 02, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company has entered into a Clinical Trial Agreement (CTA), dated August 28, ... Read More...
Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

TORONTO, Aug. 31, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company’s Phase 3 clinical trial protocol to evaluate the safety and efficacy... Read More...
Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

TORONTO, Aug. 26, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that following the U.S. Food & Drug Administration (“U.S. FDA”) approval to procee... Read More...
Revive Therapeutics to Expand Phase 3 Clinical Trial for Bucillamine in COVID-19 in Asia-Pacific and Canada

Revive Therapeutics to Expand Phase 3 Clinical Trial for Bucillamine in COVID-19 in Asia-Pacific and Canada

TORONTO, Aug. 19, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that following the U.S. Food & Drug Administration (“U.S. FDA”) approval to procee... Read More...
Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Aug. 14, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has signed a Memorandum of Understanding (“MOU”) with Attwill Medical Solutions... Read More...
Revive Therapeutics Advancing Drug Delivery Technology for Psychedelics

Revive Therapeutics Advancing Drug Delivery Technology for Psychedelics

TORONTO, Aug. 11, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce, further to its press release of June 12, 2020, that under its sponsored research partn... Read More...
Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Update Following U.S. FDA Approval of Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, Aug. 05, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that following the U.S. Food & Drug Administration (“U.S. FDA”) approval to procee... Read More...
UPDATE - Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

UPDATE – Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, July 31, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV) (OTCQB: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food & Drug Administration (“U.S. FDA”) has approved the Company ... Read More...
Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

TORONTO, July 31, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food & Drug Administration (“U.S. FDA”) has approved the Company to proceed with... Read More...
Coming Soon.
SymbolExchangePriceChangeAs of
RVV.CD
Canadian Securities Exchange - CSE Listed
Canadian Securities Exchange - CSE Listed0.50CAD-6.60%
31R.F
Frankfurt Stock Exchange
Frankfurt Stock Exchange0.34EUR-10.39%
RVV.CCP
Canadian Composite Quote/Trade
Canadian Composite Quote/Trade0.51CAD-1.92%
RVVTF.PK
US 'Other OTC' and Grey Market
US 'Other OTC' and Grey Market0.39USD-5.02%
31R.MU
Munich Stock Exchange
Munich Stock Exchange0.38EUR0.00%
31R.BE
Berlin Stock Exchange
Berlin Stock Exchange0.36EUR-3.38%
RVVTF.PQ
OTC MARKETS GROUP L1 AND L2
OTC MARKETS GROUP L1 AND L20.39USD-4.88%

Delayed data (1h)
NameAgePositionAppointed
Michael Frank
Chairman of the Board, Chief Executive Officer
--Chairman of the Board, Chief Executive Officer2019
Carmelo Marrelli
Chief Financial Officer
--Chief Financial Officer2015
Joshua Herman
Independent Director
--Independent Director2019
William Jackson
Independent Director
--Independent Director2014
Andrew Lindzon
Independent Director
--Independent Director2019
Christian Scovenna
Independent Director
--Independent Director2019


Share this page